<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Precision Profiling With PDX

Oncology drug development is inefficient and expensive, costs quickly spiral upwards while attrition rates of new agents in late-phase clinical trials are overly high.